Share on PinterestNew research is questioning the predominant hypothesis that a buildup of beta-amyloid causes Alzheimer’s disease.

Alzheimer’s disease affects over 5.5 million people in the United States and millions more around the globe.

Yet, researchers are still at a loss as to why this condition — which is characterized by memory impairment and many other cognitive problems — occurs in the first place. And until they fully understand the cause, investigators will remain unable to devise a cure.

So far, the prevailing hypothesis among experts has been that the excessive accumulation of a potentially toxic protein — beta-amyloid — in the brain causes Alzheimer’s.

Researchers have argued that beta-amyloid plaques disrupt the communication between brain cells, potentially leading to cognitive function problems.

Now, a new study from the University of California San Diego School of Medicine and the Veterans Affairs San Diego Healthcare System suggests that while the buildup of beta-amyloid has associations with Alzheimer’s, it may not actually cause the condition.

In a study paper that appears in the journal Neurology, the researchers explain what led them to reach this conclusion.

“The scientific community has long thought that amyloid drives the neurodegeneration and cognitive impairment associated with Alzheimer’s disease,” says senior author Prof. Mark Bondi.

He notes that “[t]hese findings, in addition to other work in our lab, suggest that this is likely not the case for everyone and that sensitive neuropsychological measurement strategies capture subtle cognitive changes much earlier in the disease process than previously thought possible.”

What comes first?

In their study, the researchers worked with a total of 747 participants with different levels of cognitive health. All of the study participants agreed to undergo neuropsychological assessments, as well as PET and MRI brain scans.

Of the participants, 305 were cognitively healthy, 289 had mild cognitive impairment, and 153 displayed markers of what the investigators call “objectively-defined subtle cognitive difficulties (Obj-SCD).”

Experts define mild cognitive impairment as a state of cognitive impairment that is more severe than what one would normally experience with age, but not yet severe enough for a dementia diagnosis.

However, mild cognitive impairment does develop into dementia in a significant number of people.

But what are Obj-SCD? In their paper, the investigators define them as “difficulties or inefficiencies on some sensitive cognitive tasks even though the overall neuropsychological profile is in the normal range.”

That is, they are a measurement of experienced, subtle cognitive functioning problems that occur in the absence of any visible signs of brain or psychological issues. To find out whether someone is experiencing Obj-SCD, researchers assess, among other factors, how efficiently that person can learn and retain new information.

Previous research has suggested that individuals with Obj-SCD are at a higher risk of mild cognitive impairment and forms of dementia.

In the current study, Prof. Bondi and the team found that beta-amyloid built up at a faster rate in the participants with Obj-SCD compared with those who were deemed cognitively healthy. Moreover, brain scans of people with Obj-SCD showed that these individuals experienced a thinning of brain matter in a region called the entorhinal cortex.

Past research has shown that the entorhinal cortex decreases in volume in people with Alzheimer’s disease. This is significant because this brain region plays a role in memory and spatial orientation.

The researchers also found that while people with mild cognitive impairment had higher quantities of beta-amyloid in their brains at the beginning of the study, this protein did not seem to build up any faster in these participants than it did in cognitively healthy individuals.

But why do the current findings potentially contradict a decades-old hypothesis about the development of Alzheimer’s? Prof. Bondi explains:

“This work […] suggests that cognitive changes may be occurring before significant levels of amyloid have accumulated. It seems like we may need to focus on treatment targets of pathologies other than amyloid, such as tau, that are more highly associated with the thinking and memory difficulties that impact people’s lives.”

“While the emergence of biomarkers of Alzheimer’s disease has revolutionized research and our understanding of how the disease progresses, many of these biomarkers continue to be highly expensive, inaccessible for clinical use, or not available to those with certain medical conditions,” adds first author Kelsey Thomas, Ph.D.

The new study’s findings could help change that by refocusing the research approach on more subtle markers of Alzheimer’s, such as those assessing for Obj-SCD.

“A method of identifying individuals at risk for progression to [Alzheimer’s disease] using neuropsychological measures has the potential to improve early detection in those who may otherwise not be eligible for more expensive or invasive screening,” says Thomas.

Share on PinterestScientists believe that they are on the path to a vaccine against dementia.

Globally, dementia affects an estimated 50 million people. Because dementias are primarily a disease of older age, this figure is likely to increase as the average life expectancy increases.

In fact, some scientists have calculated that the burden of dementia in the United States could double by the year 2060.

Alzheimer’s disease, which is the most common form of dementia, is characterized by changes in the brain. Specifically, there is a buildup of beta-amyloid, which is a protein that produces amyloid plaques. Similarly, another protein, known as tau, accumulates to form neurofibrillary tangles. Together, these proteins drive cognitive decline and neurodegeneration.

Currently, there is no cure for dementia, and treatments are limited. Over the years, several promising drug candidates have proven unsuccessful in human trials.

A preemptive strike

The authors of the current study believe that one of the reasons that experimental drugs have failed is because treatment is “initiated too late in the pathological process.”

They believe that once the disease mechanism is in full swing, it is more difficult to bring the brain back into a healthy state.

With this in mind, scientists are focusing their energy on developing vaccines that they can use before symptoms arise, stopping dementia in its tracks. The most recent study along these lines is now available in the journal Alzheimer’s Research & Therapy.

The authors, from the University of California, Irvine, and the Institute for Molecular Medicine in Huntington Beach, CA, investigated a combination vaccine approach.

Scientists believe that the combination of beta-amyloid plaques and neurofibrillary tangles might work together to speed up neurodegeneration. The authors of the recent study explain that these two distinct pathologies “may interact to trigger the progression from […] mild cognitive impairment” to Alzheimer’s disease.

With this in mind, the researchers attempted to target both types of protein accumulation at once. They hoped that by hitting both targets, they might be more successful than the drugs that only approach one at a time.

A new vaccine

Earlier studies in mice have demonstrated that two vaccines, known as AV-1959R and AV-1980R, produce an antibody response to beta-amyloid and tau, respectively. In the new study, the authors investigate their combined effect.

The scientists carried out their research using mice that develop pathological aggregates of tau and beta-amyloid. They developed a vaccine consisting of both AV-1959R and AV-1980R.

Importantly, the scientists delivered these drugs alongside an adjuvant called AdvaxCpG, which helps produce a stronger immune response in animals that receive the vaccine. Another author of the current paper, Prof. Nikolai Petrovsky from Flinders University in South Australia, designed this adjuvant.

As expected, the researchers found that the combination therapy induced the production of antibodies to both tau and beta-amyloid. In turn, these antibodies reduced levels of the insoluble tau and beta-amyloid that produce plaques and tangles. The authors conclude:

“Taken together, these findings warrant further development of this vaccine technology for ultimate testing in human [Alzheimer’s disease].”

Because scientists have already shown that these types of vaccines and adjuvant are safe in humans, they hope that they might soon take this research to the next level. The authors believe that within 2 years, they could bring this two-pronged vaccine to clinical trials.

Because so many previous attempts to treat dementia have failed, it is important to approach this recent study with caution. However, the suggestion that a vaccine for dementia might be on the horizon is a reason to be excited.

Earlierattempts to design a dementia vaccine have, similarly, produced positive findings but are yet to bear fruit. Although this most recent study builds on previous work and has several factors in its favor, only time will tell whether it will be effective in humans.